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Women with diminished ovarian reserve often respond poorly to controlled ovarian stimulation resulting in retrieval
of fewer oocytes and reduced pregnancy rates. It has been proposed that pre-IVF Dehydroepiandrosterone (DHEA)
adjuvant therapy may improve ovarian response and pregnancy rates in women with diminished ovarian reserve.
This meta-analysis aims to investigate efficacy of DHEA as an adjuvant to improve ovarian response and IVF
outcome in women with diminished ovarian reserve. Electronic databases were searched under the following
terms: (DHEA) and (diminished ovarian reserve) and/or (poor response). Studies were included if they reported at
least one of the following outcomes; clinical pregnancy rate, number of oocytes retrieved, miscarriage rate. We
identified 22 publications determining effects of DHEA in clinical trials. Only 3 controlled studies were eligible for
meta-analysis. There was no significant difference in the clinical pregnancy rate and miscarriage rates between
women pre-treated with DHEA compared to those without DHEA pre-treatment (RR 1.87, 95% CI 0.96-3.64; and RR
0.59, 95% CI 0.21-1.65, respectively). The number of oocytes retrieved (WMD −1.88, 95% CI −2.08, 1.67; P < 0.001)
was significantly lower in the DHEA group. In conclusion, based on the limited available evidence from a total of
approximately 200 IVF cycles, there are insufficient data to support a beneficial role of DHEA as an adjuvant to
controlled ovarian stimulation in IVF cycle. Well-designed, randomised controlled trials as well as more exact
knowledge about DHEA mechanisms of action are needed to support use of DHEA in standard practice for
poor-responders.
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In vitro fertilization (IVF)Background
Ovarian ageing, as manifested by reduced ovarian re-
serve, is responsible for the well-established observation
of age related decline in fertility [1,2] and of age related
increase in adverse reproductive events such as miscar-
riages [3] and aneuploid pregnancies [4]. While ovarian
ageing is one of the major determinants of outcome
following in-vitro fertilization (IVF), women with re-
duced ovarian reserve often respond poorly to controlled
ovarian stimulation resulting in retrieval of fewer oo-
cytes, producing poorer quality embryos and reduced* Correspondence: mzxan@nottingham.ac.uk
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distribution, and reproduction in any mediumimplantation rates and pregnancy rates. Incidence of
poor ovarian response, a measure of reduced ovarian re-
serve, ranges from 9-24% in the earlier report [5] but is
increasing [6] because of global rise in the number of
women who defer conceiving to their 30s or 40s. Various
treatment regimens including different stimulation pro-
tocols and adjuvant therapies have been reported to im-
prove ovarian response and pregnancy rates in women
with diminished ovarian reserve but none of them have
been proven to be superior over the others to recom-
mend any one of them as the best protocol of choice [7].
It has been proposed that oral administration of Dehy-
droepiandrosterone (DHEA), an adrenal androgen, may
have anti-ageing effects and may improve ovarian re-
sponse and pregnancy rates in women with reduced
ovarian reserve during IVF. Casson et al., in the yearentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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replacement therapy (HRT) were the first group that
reported the benefits of DHEA supplementation for im-
proving the response to ovarian stimulation in a case
series [8]. Since then, a few controlled studies including
a randomised controlled study, but with small sample
sizes, have subsequently reported benefits of DHEA
supplementation to improve ovarian response and IVF
outcome [9]. While the mechanism of action for this im-
proved IVF outcome following DHEA administration re-
mains speculative, controlled studies have demonstrated
oral DHEA supplementation increases serum IGF-I con-
centrations, which are known to have a positive effect
on follicular development and oocyte quality. Further, it
is well established that androgens can directly influence
ovarian follicle development by local intra-ovarian an-
drogen receptor mediated actions [10,11] and it is there-
fore possible that DHEA may enhance the follicular
environment through: augmentation of the growth pro-
moting and survival enhancing effect of IGF-I; LH-
stimulated follicular androgen and oestrogen production
[12]; and the augmentation of granulosa cell FSH-
receptor (FSH-r) expression and associated increase in
the number of growing preantral and small antral folli-
cles [13,14]. In addition, given the published report of
DHEA on reducing miscarriage rates in older patients, a
direct- or indirect- effect of DHEA at the level of the oo-
cyte cannot be ruled out. DHEA could potentially im-
prove oocyte quality via the GH axis through the
promotion of DNA repair in oocytes [15]. An effect of
DHEA on mitochondrial activity in both follicular cells
and oocytes is also possible since androgens have been
shown to beneficially affect mitochondrial function [16].
A recent world-wide survey has shown that over a
quarter (26%) of IVF clinicians add DHEA as an adju-
vant to IVF treatment protocols in women with poor
ovarian response [6]. Despite widespread use of DHEA,
clinical evidence as well as knowledge regarding under-
lying mechanisms of DHEA on improvement of ovarian
response is still limited. A recent systematic review by
Sunkara et al. investigating the role of androgens (tes-
tosterone, DHEA, and aromatase inhibitor- Letrozole)
in poor-responders undergoing IVF treatment could not
show significantly improvement in terms of pregnancy
rates and other parameters such as number of oocytes
retrieved [17]. While Sunkara et al.’s review included all
the androgen adjuvants, there is no systematic review
and meta-analysis reported specifically on the role of
DHEA alone in women with diminished ovarian re-
serve. This systematic review aims to summarize the
role of DHEA as an adjuvant to stimulation protocol in
women with diminished ovarian reserve or poor-
responders based on meta-analysis of the published
controlled studies.Methods
We searched EMBASE (1980 to December 2012),
MEDLINE (1948 to December 2012), Pubmed and
Cochrane Library for all relevant articles under the follow-
ing Medical Subject Headings (MeSH) terms to generate
subsets of studies; i) ‘DHEA’ or Dehydroepiandrosterone’,
ii) ‘Poor response’ or ‘low response’, and iii) ‘Diminished
ovarian reserve’ or ‘Premature ovarian aging’. Combining
these subsets together (subset i with either ii or iii) by
‘AND’ to identify citations appropriate to the question
‘The effect of DHEA supplementation on ovarian stimula-
tion outcomes in diminished ovarian reserve and/or poor
responses patients’. The search also tracked on ISI confer-
ence abstracts as well as on-going randomised controlled
trials registered on ISRCTN database. In addition, all pri-
mary papers’ bibliographies were explored to recognize
cited publications which had not been identified by
electronic-based searches. Only articles written in English
were included in the meta-analysis. The searches were
conducted by two reviewers independently (AN and KJ).
The target population was either poor-responders or
those with diminished ovarian reserve, as described
above, who were undergoing ovarian stimulation plus
IVF/ICSI. DHEA was supplemented before ovarian
stimulation in the study group while neither was used in
the control. The primary outcome was the clinical preg-
nancy rate and the secondary outcomes were oocyte
yield (numbers of oocytes retrieved), miscarriage rate,
live birth rate and aneuploidy rates.
All full manuscripts were reviewed for the selection
and exclusion of publications with predefined inclusion
criteria by two reviewers (AN and KJ) independently.
Extraction data for each study, e.g. study design, inclu-
sion/exclusion criteria, population characteristics, defin-
ition of diminished ovarian reserve, stimulation protocol,
and outcomes, was separately done by two of the au-
thors (AN and KJ) using pre-determined tables and
form. Disagreements about either article selection or
data extraction were resolved by consensus or arbitra-
tion by a third reviewer (BKC). The Newcastle-Ottawa
Scale (NOS) scoring system [18] was used to assess
methodology and quality of observational studies (non-
randomised trials). For RCT, the full publication was
scrutinized to identify study characteristics; randomisa-
tion, allocation, blinding, and intention-to-treat analysis.
Statistical analysis
Relative risks (RR) from individual studies were analysed
using random effects models [19]. Heterogeneity of ex-
posure effects was evaluated graphically using forest
plots (Lewis and Clarke, 2001) and statistically using the
I2 statistic to quantify heterogeneity across studies [20].
Statistical analyses were performed using RevMan 5.1
software (Cochrane Collaboration, Oxford, UK).
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The search yielded 38 publications of which 16 excluded
by screening through titles and abstracts, including one
paper that is not published in English. Full manuscripts
were retrieved for the remaining 22 articles, which in-
cluded 3 case series [21-23], 3 case-control [24-26], 7 pro-
spective self-controlled studies [8,12,27-31], 1 randomised
controlled trial (RCT) [9], 3 abstract oral/poster presenta-
tions [32-34], and 5 reviews [22,35-38]. Studies that have
matched controls were identified eligible for analyses.
Study characteristics of controlled studies are presented in
Table 1 whereas quality of all studies included in the
meta-analysis is shown in Table 2.
Primary outcome: clinical pregnancy rate
Only two studies, one RCT [9] and one non-RCT [25],
were selected for meta-analysis for the clinical pregnancy
rate (CPR) outcome. Due to the fact that Wiser’s study
reported cumulative pregnancy outcome over two con-
secutive IVF cycles, only first cycle data was taken into
account. Pooling data together (Figure 1A), there was no
significant difference in the clinical pregnancy rate be-
tween women pre-treated with DHEA compared to those
without DHEA pre-treatment (RR 1.87, 95% CI 0.96, 3.64;
P=0.07). While there was homogeneity observed between
the two included studies (I2< 1%), the study designs were
completely different as one was a case control study and
the other, a randomised controlled trial.
Secondary outcome: miscarriage rate
Similar to primary outcome, only two published con-
trolled studies were eligible for analysis [9,25]. The re-
sults from these studies showed that there was no
difference between the DHEA and control groups (RR
0.59, 95% CI 0.21, 1.65; Figure 1B).
Further literature review revealed one particularly retro-
spective study from Gleicher et al. (2009) which specifically
examines miscarriage rates. In this study, they reported
that DHEA supplemented pregnancies in women with di-
minished ovarian reserve had lower miscarriage rates when
compared to the national United States IVF database (OR
0.49; P=0.04) [26]. Because of lack of comparability be-
tween cases and controls, who did have diminished ovarian
reserve and who did not, this study was therefore, excluded
from meta-analysis.
Oocytes retrieved
Regarding number of oocytes, meta-analysis of the three
studies, one RCT [9] and two non-RCT [24,25], demon-
strated a significantly lower number of oocytes retrieved
in DHEA treated women when compared to the con-
trols (WMD -1.88, 95% CI -2.08, -1.67). However, a sig-
nificant heterogeneity of 74% (I2) among studies was
observed (Figure 2).Discussion
This systematic review of the controlled studies that
reported the effect of pre-treatment DHEA on IVF out-
come in women with diminished ovarian reserve sug-
gests that DHEA does not improve the quantitative
ovarian response and pregnancy outcome. While the
ovarian response as defined by the number of oocytes
retrieved was significantly lower, the clinical pregnancy
rate was marginally superior with a relative risk of 1.87
(95% CI 0.96-3.64; P=0.07) in the DHEA group. The
miscarriage rate was similar between the DHEA and
control groups on meta-analysis of the two reported
controlled studies. This finding, however, is based on
few data as there was only one study [9] which reported
live birth rate, which was similar between the DHEA
and control groups when only one cycle per participant
was considered for analysis.
While there are several self-controlled case series on
reported significant benefits in terms of ovarian response
and pregnancy rates with the use of pre-treatment
DHEA adjuvant during IVF, this systematic review of
controlled studies failed to demonstrate such a benefit.
However, while noting the trend of a positive effect of
DHEA on the pregnancy rate in this review, the lack of a
significant difference may be because of a small sample
size with the overall number of participants that are in-
cluded in the meta-analysis is only 198. In the study of
Barad et al. 2007 included in this review, the authors
have also reported spontaneous pregnancy (n=6/16) and
pregnancy following IUI (6/9), which occurred during
the three to four months waiting time of pre-IVF DHEA
adjuvant treatment [25]. When these data were included
in the meta-analysis, there was a significantly increased
pregnancy rates in the DHEA arm over the controls (RR
2.46 95% CI 1.35, 4.48; P=0.003). Since our objective was
to investigate the effect of DHEA in IVF cycle, we have in-
cluded only the IVF population in the primary analysis.
At present, there is only a single small randomised
controlled trial by Wiser et al. 2010 reported in literature
[9]. The small sample size in this study resulted in only a
minimal effect toward the result of the meta-analysis
(Figures 1 and 2). Furthermore, many limitations and
weaknesses of Wiser’s study have been criticised. First,
there was no priori sample size estimation in the study.
The authors included two cycles with varying duration of
DHEA adjuvant treatment (7 – 18 weeks) and the authors
continued the trial until a significant difference in cumula-
tive live birth rate between the study and control groups
was achieved. There was no difference in the live birth
rate between the study and control groups following their
first cycle of IVF with the mean duration of DHEA ther-
apy in the study group was for only about 8.5 weeks. Sec-
ondly, both patients and health care providers were not
blinded in this study therefore bias could occur, or
Table 1 Study characteristics of controlled studies (both RCT and non-RCTs) of DHEA supplementation in poor-responders or diminished ovarian reserve
Articles Study
design
Inclusion criteria Cases/ Controls Intervention
(DHEA doses
and duration)
Stimulation
protocol
Embryo transfer Outcomes Notes
Barad D, et al.
(2007)
Case–
control
POA defined by age-
specific baseline FSH
levels > 95% CI of mean
value for the age group;
but < 12 mIU/ml
DOR defined as baseline
FSH > 12 mIU/ml and/or
estradiol level≥ 75 pg/ml
89 cases* and 101
controls *only 64 of
89 undergoing IVF
Cases : DHEA 25 mg
three times daily for
mean duration 73
days continuously
until
-Allow cases to
conceive naturally;
the other entered IVF
using microdose
agonist
Day 3 embryo
transfer
-Clinical
pregnancy rate
-No. of retrieved
oocytes
-Implantation rate
-Miscarriage rate
-Normal day 3
embryos
-Time from initial
visit to pregnancy
(Cox regression
analysis)
-Cases were slightly
older (P < 0.05)
-Fertility treatments
were different
(P < 0.001)
-Women in control
entered IVF cycle
more rapidly
positive pregnancy
test
flare followed by high
dose FSH + HMG
(300–450 + 150 IU)
Control : None -Similar protocol for
both cases/controls
Wiser A, et al.
(2010)
RCT (open-
labeled)
Age≤ 41 yr, Poor
response, previous IVF
cycle with high dose Gn
(FSH 300 IU) with oocyte
<5 or cycle cancellation
17 Cases Cases : DHEA 75 mg/
day orally ≥ 6 weeks
before stimulation
- Similar protocol for
both cases/controls
Day 2–3 embryo
transfer
-Peak estradiol
levels
Counted 55 IVF
from 33 patients
(both arms went
through
16 Controls Control : None - Standard long GnRH
agonist protocol
Up to 3 embryos -No. of retrieved
oocytes
Including of
repeat cycles
without
adjustment of
randomisation
- Using rFSH 450 IU +
rLH 150 IU
-Embryo quality
and No. of reserve
embryo
Gleicher N, et al.
(2010)
Case–
control
DOR defined by
abnormally age specific
hormone levels deviated
from 95% CI; elevated
FSH or low AMH
22 Cases Cases : DHEA 25 mg
three times daily
At least 4 weeks
before stimulation
Microdose agonist
flare followed by high
dose FSH + HMG
(300–450 + 150 IU)
Not being stated -Pregnancy and
live birth rates
(secondary
outcome)
Clinical pregnancy
rate, miscarriage
and No. of oocyte
retrieved (our
outcomes) are not
the main
outcome of the
study.
44 matched Controls
(1st single IVF cycle
analysis only)
-Similar protocol for
both cases/controls
Pregnancy was
not outcome of
interest
-Aneuploidy rate
Control : None -No. of oocytes
retrieved
-Total
gonadotropin
dosage
*POA: Premature Ovarian Aging, DOR: Diminished Ovarian Reserve.
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Table 2 Quality of controlled studies passing eligibility criteria presented by stratification of research methodology
and Newcastle-Ottawa scalea (for non-randomised observational studies)
Author/Year Design Randomisation Blinding Sample
size estimation
Analysis Newcastle-Ottawa scale
Selection Comparability Outcome
Barad D, et al.
(2007)
Case -control
study
None None N/A Intention to treat
analysis
*** * **
Wiser A, et al.
(2010)
Randomised
controlled study
-Computer generated
random numbers
None Not done Intention to treat
analysis
- allocation concealment
by sealed envelope
(No-drop out)
Gleicher N, et al.
(2010)
Case -control
study
None None N/A Intention to treat
analysis
*** * ***
a Wells GA et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality if nonrandomized studies in meta-analysis, available from: URL: http://www.ohri.ca/
programs/clinical_epidemiology/oxford.asp [cited 2012 June 1].
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the-counter medication for themselves. And finally, one
letter to the editor expressed concern over the statistical
analysis in this study suggesting that because the author
had included two consecutive IVF cycle data from each
group, Kaplan-Meier survival analysis should have been
used rather than Fisher’s exact test, which was originally
reported [39].
Most data on the favourable effect of DHEA adjuvant
supplementation currently come from the study group
led by Barad and Gleicher at the Centre of Human
Reproduction, New York. They have published a series
of self-controlled studies and retrospective case control
analyses in which the benefits of DHEA are summarized
as follows; i) increased oocyte yield [12] ii) higher
fertilization rate [12] iii) improved embryo morphologicalFigure 1 Meta-analysis of clinical pregnancy and miscarriage rates. M
outcome of A) clinical pregnancy rates and B) Miscarriage rates in DOR orgrading [12] iv) increased pregnancy rate [25], v) lower
miscarriage rate when compared to the national IVF sta-
tistics [26], and vi) lower aneuploidy rate [24]. We have in-
cluded two of their suitable controlled studies in our
meta-analysis (Table 1). The authors also suggested that
the benefit of DHEA treatment would be most effective if
it is supplemented for at least 3-4 months, which is equal
to the time needed for the early growing follicles to reach
the gonadotropin-responsive stage [35]. Therefore, they
believed that DHEA acts in both ovarian recruitment and
early folliculogenesis. If this hypothesis is true, the dur-
ation of DHEA treatment is possibly a key factor in
effecting a favourable change in ovarian response and
pregnancy rates following IVF.
The data from the self-controlled studies should be
interpreted with caution because of potential bias. Ineta-analysis of studies of DHEA supplementation versus controls for
poor responders undergoing IVF cycle.
Figure 2 Meta-analysis of numbers of oocytes. Meta-analysis of studies of DHEA supplementation versus controls for outcome of numbers of
oocytes retrieved in DOR or Poor responders undergoing IVF cycle.
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ively analysed IVF outcome in the second cycle of 801
patients who have history of poor ovarian response (pro-
duction of ≤ 4 oocytes) in the first IVF cycle treatment in
their centre. It was found that almost 40% of this cohort
developed better response yielding more than 4 oocytes
in their next cycle [37]. These data also confirm that
poor response cannot be predicted only by history.
Using other predictive tools to determine ovarian re-
serve, for instance antral follicle count or serum AMH,
or both, is also critical to identify patients who will
mostly benefits from DHEA in the clinical trial [40].
This systematic review did not include any self con-
trolled studies, but included only the studies that had a
group of contemporaneous controls. Our results in this
review indicate that DHEA decreases the ovarian re-
sponse as indicated by reduced number of oocytes re-
trieved at egg collection in the study arm. While this
finding is surprising and it is difficult to come up with a
scientific explanation, this systematic review is limited
by a small number of treatment cycles included in the
meta-analysis and by the heterogeneity of the included
studies. On the contrary to the above finding, as indi-
cated by trends of improving clinical pregnancy and of
reducing miscarriage albeit no statistical significance,
DHEA may have a positive effect on improving oocyte
and embryo quality. It is already established that poor
oocyte quality, which leads to producing poorer quality
embryos, represents one of the clinical presentations of
ovarian ageing [41]. The finding of potential effects of
DHEA on oocyte quality and ovarian response warrant
well-designed randomised controlled clinical trials of an
adequate sample size using well-defined uniform inclu-
sion criteria before recommending the use of DHEA in
standard assisted reproduction treatment. In addition,
further in-vivo and in-vitro embryological and endo-
crinological research to elucidate the mechanism of ac-
tion of DHEA on ovarian folliculogenesis and on oocyte/
embryo quality are also required.
Recent meta-analysis which evaluated the effect of ad-
juvant androgens (DHEA or Testosterone) or androgen-modulating agents (Letrozole, aromatase inhibitor) in
previous poor responders has failed to demonstrate any
significant difference in the ongoing pregnancy rate, live
birth rates, and numbers of oocytes retrieved when com-
pared with the control group, who have had no adjuvant
therapy [17]. Another systematic review by Bosdou et al.
2012 reports a significant increase in clinical pregnancy
and live birth rates in poor responder women who are
pre-treated with transdermal testosterone, but not in
other androgen modulating agents including DHEA,
when compared to controls [42]. The review by Bosdou
et al. on DHEA included only one study with a small
sample size (n=33) in contrast to this review in which
we included two other eligible controlled studies with
larger sample sizes. However, it is important to note that
all the reviews including ours are still limited by small
sample sizes and heterogeneity between the studies
included. In addition, there is a wide methodological
variation in different studies in terms of different prepa-
rations that are used as adjuvants, and duration and
timing, in relation to down regulation and ovarian
stimulation during IVF, of adjuvant treatments. This
conflicting data regarding the use of androgen and an-
drogen modulating agents require further investigation
by well-designed randomised controlled trials.
Conclusions
In conclusion, our systematic review of the controlled
studies on the effect of pre-treatment DHEA on IVF
outcome in women with diminished ovarian reserve
suggests that DHEA does not improve the quantitative
ovarian response and pregnancy outcome. Based on
these data, DHEA adjuvant therapy cannot be re-
commended in diminished ovarian reserve for improv-
ing IVF outcome. However, as the sample size in this
analysis was small and the effect of DHEA on preg-
nancy rates approached close to statistical significance,
further large scale multicentre randomised controlled
studies are required to clarify the benefits of DHEA ad-
juvant therapy in routine clinical management of pre-
dicted poor responders.
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